Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 117 Triple Negative Breast Neoplasms 27 Neoplasm Metastasis 18 Sarcoma 17 Neoplasms 16 Carcinoma, Non-Small-Cell Lung 7 Ovarian Neoplasms 6 Brain Neoplasms 5 Prostatic Neoplasms 4 Urinary Bladder Neoplasms 3 Unspecified Adult Solid Tumor, Protocol Specific 3 Liposarcoma 3 Inflammatory Breast Neoplasms 3 HER2-negative Breast Cancer 3 Carcinoma, Transitional Cell 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Melanoma 2 Lymphoma 2 Lung Neoplasms 2 Leiomyosarcoma 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma 2 Advanced Breast Cancer 2

Interventions

Acupuncture Therapy 10 Exercise 7 Cryotherapy 6 Paclitaxel 5 Glutamine 5 Surveys and Questionnaires 3 Duloxetine Hydrochloride 3 Dexamethasone 3 Bortezomib 3 Acetylcysteine 3 Thioctic Acid 2 Tablets 2 Sodium Chloride 2 Saline Solution 2 Physical Therapy Modalities 2 Low-Level Light Therapy 2 Lenalidomide 2 Fish Oils 2 Fatty Acids, Omega-3 2 ziconotide 1 sagopilone 1 pembrolizumab 1 nicotinamide-beta-riboside 1 nabilone 1 glutamic acid diethyl ester 1 eribulin 1 enfortumab vedotin 1 allantoicase 1 Yoga 1 XELOX 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Peripheral Nervous System Diseases × eribulin × Clear all

NCT03027245 2022-07-13

IRENE

Eisai Inc.

Breast Neoplasms, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡